Follow
Tomás Pascual Martínez
Tomás Pascual Martínez
Medical Oncologist, Hospital Clinic Barcelona. SOLTI
Verified email at clinic.cat
Title
Cited by
Cited by
Year
Immune-related gene expression profiling after PD-1 blockade in non–small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma
A Prat, A Navarro, L Paré, N Reguart, P Galván, T Pascual, A Martínez, ...
Cancer research 77 (13), 3540-3550, 2017
3792017
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
F Schettini, N Chic, F Brasó-Maristany, L Paré, T Pascual, B Conte, ...
NPJ breast cancer 7 (1), 1, 2021
3482021
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
O Martínez-Sáez, N Chic, T Pascual, B Adamo, M Vidal, B González-Farré, ...
Breast cancer research 22, 1-9, 2020
2242020
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label …
A Prat, C Saura, T Pascual, C Hernando, M Muñoz, L Paré, BG Farré, ...
The Lancet Oncology 21 (1), 33-43, 2020
1382020
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade
A Prat, T Pascual, C De Angelis, C Gutierrez, A Llombart-Cussac, T Wang, ...
JNCI: Journal of the National Cancer Institute 112 (1), 46-54, 2020
1182020
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis
F Schettini, T Pascual, B Conte, N Chic, F Brasó-Maristany, P Galván, ...
Cancer treatment reviews 84, 101965, 2020
1152020
The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer
E Ciruelos, T Pascual, MLA Vozmediano, M Blanco, L Manso, L Parrilla, ...
The Breast 23 (3), 201-208, 2014
1102014
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
G Griguolo, T Pascual, MV Dieci, V Guarneri, A Prat
Journal for immunotherapy of cancer 7, 1-14, 2019
1052019
Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer
JM Cejalvo, T Pascual, A Fernández-Martínez, F Brasó-Maristany, ...
Cancer treatment reviews 67, 63-70, 2018
1022018
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual …
P Nuciforo, T Pascual, J Cortés, A Llombart-Cussac, R Fasani, L Paré, ...
Annals of Oncology 29 (1), 170-177, 2018
982018
Palbociclib and trastuzumab in HER2-positive advanced breast cancer: results from the phase II SOLTI-1303 PATRICIA trial
E Ciruelos, P Villagrasa, T Pascual, M Oliveira, S Pernas, L Paré, ...
Clinical Cancer Research 26 (22), 5820-5829, 2020
852020
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
L Paré, T Pascual, E Seguí, C Teixidó, M Gonzalez-Cao, P Galván, ...
Annals of Oncology 29 (10), 2121-2128, 2018
852018
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
F Brasó-Maristany, G Griguolo, T Pascual, L Paré, P Nuciforo, ...
Nature communications 11 (1), 385, 2020
802020
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study
V Guarneri, MV Dieci, G Bisagni, A Frassoldati, GV Bianchi, GL De Salvo, ...
Annals of Oncology 30 (6), 921-926, 2019
762019
De-escalation of treatment in HER2-positive breast cancer: determinants of response and mechanisms of resistance
J Veeraraghavan, C De Angelis, JS Reis-Filho, T Pascual, A Prat, ...
The Breast 34, S19-S26, 2017
632017
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
A Prat, V Guarneri, T Pascual, F Braso-Maristany, E Sanfeliu, L Pare, ...
EBioMedicine 75, 2022
622022
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
A Prat, V Guarneri, L Paré, G Griguolo, T Pascual, MV Dieci, N Chic, ...
The Lancet Oncology 21 (11), 1455-1464, 2020
622020
Neoadjuvant management of early breast cancer: a clinical and investigational position statement
R Colomer, C Saura, P Sánchez‐Rovira, T Pascual, IT Rubio, O Burgués, ...
The Oncologist 24 (5), 603-611, 2019
582019
Intrinsic molecular subtypes of HER2+ breast cancer
A Prat, T Pascual, B Adamo
Oncotarget 8 (43), 73362, 2017
442017
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis
S Garcia-Recio, T Hinoue, GL Wheeler, BJ Kelly, AC Garrido-Castro, ...
Nature Cancer 4 (1), 128-147, 2023
372023
The system can't perform the operation now. Try again later.
Articles 1–20